Daily Pharma News - 27 October 2026

Welcome to today's daily pharma news roundup from PharmacoLearn, covering the most important pharmacy, drug regulation and pharmaceutical industry stories from India and around the world on 27 October 2026. From cancer drug price control in India to a world-first stroke medicine approval in China, today's stories matter for every pharmacy student, pharmacist and healthcare professional following drug pricing, drug approvals and new drug delivery systems.

NPPA Caps Trade Margins on 137 Cancer Drugs in India: Prices May Fall up to 70 Percent from 9 November 2026

India's National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30 percent on 137 non-scheduled anti-cancer drugs, including widely used oncology medicines such as pembrolizumab and osimertinib. The revised prices will apply from 9 November 2026, and the move is expected to bring annual savings of about Rs 2,500 crore for patients and the healthcare system. For pharmacy students, this is a textbook example of how drug price regulation works outside the scheduled drug list, where margin control rather than a fixed ceiling price is used to improve medicine affordability.

Cancer treatment in India remains one of the largest out-of-pocket expenses for families, so a price fall of up to 70 percent on some of these drugs could change access to oncology treatment in a meaningful way. Students should note the role of the NPPA under the Department of Pharmaceuticals, the difference between scheduled and non-scheduled formulations under the Drug Price Control Order, and how trade margin rationalisation affects manufacturers, distributors, retailers and hospital pharmacies alike.

JP Nadda Launches Capacity Building Programme for Drug De-addiction Services in India

Union Health Minister J. P. Nadda launched a capacity-building programme on 26 October 2026 for doctors, nurses and counsellors working in substance-use prevention, assessment and treatment services. The programme supports the Nasha Mukt Bharat Abhiyaan goal of a drug-free India by 2029, and it recognises that de-addiction care depends as much on trained healthcare professionals as on medicines themselves. Pharmacists play a vital role here, from counselling on de-addiction pharmacotherapy to identifying substance misuse and referring patients to the right services.

For pharmacy students, this story connects pharmacology, community pharmacy practice and public health policy. Understanding substance-use disorders, withdrawal management, opioid substitution therapy and the psychosocial side of addiction treatment is increasingly important in clinical pharmacy, and trained professionals across the primary healthcare system will be central to delivering these services in every district of India.

Kerala Defends Cheaper Generic Risdiplam for Spinal Muscular Atrophy Patients

The Kerala government told its Assembly on 26 October 2026 that CDSCO-approved generic risdiplam costs about Rs 15,000 for 12 days, compared with about Rs 6.5 lakh for Roche's branded version, easing the financial burden on families of spinal muscular atrophy (SMA) patients. The state also expressed hope for a further price cut to Rs 9,000. Spinal muscular atrophy is a rare genetic disorder that causes progressive muscle weakness, and risdiplam is an oral disease-modifying therapy that helps patients produce more functional survival motor neuron protein.

This South India story is a powerful case study in generic drug access, rare disease policy and state-level healthcare decision-making in India. For pharmacy students, it highlights how CDSCO approval of quality generics, state procurement and public debate over drug pricing can directly decide whether a life-changing medicine reaches patients, and why pharmacoeconomics and generic substitution are central topics in modern pharmacy education.

China NMPA Approves Bayer Asundexian Sunharbo: World's First Factor XIa Inhibitor for Stroke Prevention

China's National Medical Products Administration (NMPA) approved Bayer's asundexian 50 mg, marketed as Sunharbo, on 26 October 2026 to reduce stroke risk after non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack (TIA). The approval followed priority review and the OCEANIC-STROKE trial data, making asundexian the first Factor XIa inhibitor approved anywhere in the world. Factor XIa inhibition is a new frontier in anticoagulation, aiming to prevent clot formation while reducing bleeding risk compared with traditional anticoagulants.

For pharmacy students studying anticoagulant pharmacology, this is a landmark development to watch closely. The Factor XIa class could reshape secondary stroke prevention, and the China-first approval shows how regulatory pathways, priority review and large cardiovascular outcome trials now drive global drug development. Students should follow how other regulators, including the US FDA and the European Medicines Agency, respond to this new mechanism of action in the coming years.

Russia Trials New GPR119 Capsule Drug Depyarone for Type 2 Diabetes and Obesity

Researchers in Volgograd, Russia, have begun human trials of Depyarone, a gut-acting GPR119 capsule designed to stimulate the body's natural hormones for type 2 diabetes and obesity management. Phase 2 trials will test doses in 308 people with type 2 diabetes, and the drug is claimed to have minimal penetration into the bloodstream, acting mainly in the gut. GPR119 agonists work by stimulating incretin and insulin release pathways, an approach that has attracted interest as an alternative or complement to existing diabetes therapies.

This early-stage story is a useful reminder that drug discovery is a long pipeline, and that most experimental medicines never reach the market. For pharmacy students, it is a good opportunity to revise G-protein coupled receptor pharmacology, incretin biology and the design of phase 1 and phase 2 clinical trials, as well as the growing global focus on oral, gut-targeted therapies for diabetes and obesity.

FDA Approves Talazoparib Plus Enzalutamide Talzenna-Xtandi for HRR-Mutated Metastatic Prostate Cancer

The US Food and Drug Administration (FDA) approved talazoparib plus enzalutamide on 26 October 2026 for metastatic prostate cancer with homologous recombination repair (HRR) gene mutations, expanding the use of the Talzenna-Xtandi combination to earlier, androgen pathway modulation-naive or sensitive disease. The approval was based on the TALAPRO-3 trial, which showed a 52 percent reduction in the risk of disease progression or death, although overall survival data remain immature. Talazoparib is a PARP inhibitor and enzalutamide is an androgen receptor inhibitor, and their combination targets cancer cells with defective DNA repair.

For Indian pharmacy students, this approval matters because PARP inhibitor combinations and biomarker-guided oncology are increasingly part of clinical practice in India as well. Understanding HRR mutations, BRCA testing, PARP inhibitor pharmacology and combination therapy in prostate cancer will help students follow oncology guidelines, hospital pharmacy practice and the growing field of precision medicine.

Aptar Pharma Acquires Pulmotree to Advance Kolibri Non-Propellant Inhaler for Lung Drug Delivery

Aptar Pharma acquired Munich-based Pulmotree on 26 October 2026 to accelerate its Kolibri non-propellant liquid inhaler, a platform for targeted pulmonary drug delivery of complex molecules including biologics. The acquisition builds on a collaboration between the two companies since 2024, and reflects growing interest in inhaler devices that avoid propellants while delivering drugs directly to the lungs. Pulmonary drug delivery is critical for respiratory diseases, and non-propellant systems also answer environmental concerns around traditional pressurised metered-dose inhalers.

For pharmacy students, this industry story connects pharmaceutics, inhalation device technology and drug delivery science. Device design, aerosol particle size, lung deposition and patient inhaler technique all decide whether a respiratory medicine works in real life, and innovations like Kolibri show why pharmaceutical technology and medical device development are core parts of a modern pharmacy career.

Conclusion

Today's news ties together the three forces shaping pharmacy in 2026: affordability, innovation and access. India is cutting the cost of cancer and rare-disease medicines through price regulation and generics, China has approved a world-first anticoagulant mechanism, Russia is testing a new gut-targeted diabetes therapy, the FDA has expanded a precision oncology combination, and inhaler technology is moving toward greener, more targeted lung delivery. For pharmacy students, the lesson is clear: stay current with drug approvals, pricing policy and new drug delivery systems, because the medicines and devices you study today will be the standard treatments you dispense, counsel on and evaluate tomorrow.

References

← All daily news